(Q57244256)

Scott B. Patten

4

0 references

Nathalie Jetté

7

Nathalie Jetté

0 references

Susan E Bronskill

8

Susan E. Bronskill

0 references

John P Hirdes

10

John P. Hirdes

0 references

author name string

Colleen J. Maxwell

1

0 references

Mary Vu

2

0 references

David B. Hogan

3

0 references

Micaela Jantzi

5

0 references

Marie-Jeanne Kergoat

https://scigraph.springernature.com/pub.10.1007/s40266-013-0083-y

6

0 references

publication date

20 April 2013

0 references

published in

Drugs & Aging

0 references

volume

30

0 references

issue

7

0 references

page(s)

569-585

0 references

exact match

0 references

cites work

Costs of informal care for people suffering from dementia: evidence from a danish survey

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Net costs of dementia by disease stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Making Alzheimer's and dementia research fit for populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

The age gap between patients in clinical studies and in the general population: a pitfall for dementia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Dementia care costs and outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Antipsychotic use and myocardial infarction in older patients with treated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Donepezil use in US nursing homes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Longitudinal medication usage in Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

A population-based study of cholinesterase inhibitor use for dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated health information system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Minimum data set for home care: a valid instrument to assess frail older people living in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Comprehensive clinical assessment in community setting: applicability of the MDS-HC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

A review of evidence on the reliability and validity of Minimum Data Set data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

MDS Cognitive Performance Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Development of a minimum data set-based depression rating scale for use in nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Validation of the Minimum Data Set Cognitive Performance Scale: agreement with the Mini-Mental State Examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

The aggressive behavior scale: a new scale to measure aggression based on the minimum data set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Temporal and Geographic variation in the validity and internal consistency of the Nursing Home Resident Assessment Minimum Data Set 2.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Validating diagnostic information on the Minimum Data Set in Ontario Hospital-based long-term care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Mental health-related drug utilization among older adults: prevalence, trends, and costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Discontinuing donepezil or starting memantine for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Factors associated with persistence of cholinesterase inhibitor treatments in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

Inappropriate Prescribing Before and After Nursing Home Admission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0083-Y

21 January 2018

Memantine for dementia

1 reference

12 December 2020

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

1 reference

12 December 2020

A comprehensive profile of the sociodemographic, psychosocial and health characteristics of Ontario home care clients with dementia

1 reference

12 December 2020

Patterns of dementia treatment use in assisted living facilities: a cross-sectional study of 1975 demented residents

1 reference

12 December 2020

Representation of patients with dementia in clinical trials of donepezil.

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

Scaling ADLs within the MDS

1 reference

12 December 2020

Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes

1 reference

12 December 2020